Blueprint Genetics is a genetic testing company based in Helsinki, San Francisco and Dubai, with a customer base spanning over 40 countries. We provide world-class genetic diagnostics and clinical interpretation for rare inherited diseases in 14 medical specialties.
What we do
We do high quality genetics testing for a global clinical community. By combining a state of the art laboratory process, the latest sequencing technology, AI empowered data-crunching tools and techniques, world-class professionals and a holistic customer experience approach, we are leading the way of changing mainstream healthcare of tomorrow.
Our promise
We provide clinicians, and their patients, with comprehensive and high-quality tools and resources for diagnostics of genetic conditions. In doing so, we provide possibilities for targeted treatment and individualized care for patients.
Key facts
Based In
Helsinki
San Fransisco
Dubai
140+
Employees
> 2000
Clinicians in 40 countries
Founded In
2012
Quality Management
CLIA
Clinical laboratory certification by US regulatory authority
CAP
All laboratory functions accredited by College of American Pathologists
ISO 15189
Our processes and documentation comply with the most widely used standards worldwide
Founders
Tommi is the CEO and co-founder of Blueprint Genetics, a clinical genetics company based in Helsinki, San Francisco, and Dubai. He has been running Blueprint Genetics since the beginning and is responsible for sales management, business development and financing. Tommi spends time in Bay Area regularly and is a regular speaker in life science and tech conferences in both US and Europe. Prior to Blueprint Genetics, Tommi founded a data analytics company called Whitevector and grew it to the Nordics and UK. Tommi holds a M.Sc. (Tech) from the Helsinki University of Technology where he studied business strategy and applied mathematics.
Juha is the Laboratory Director and Chief Medical Officer of Blueprint Genetics. He is a co-founder of the company as well. Juha is responsible for supervising laboratory production and for designing new diagnostic tests. On a daily basis, he participates in the clinical evaluation of genetic findings and further develops the company's variant classification and interpretation practices in collaboration with a team of geneticists. Juha has a MD-PhD from the University of Turku. In 2006, Juha completed his fellowship program in clinical physiology and nuclear medicine. The following year, he became a docent. From 2007 to 2009, he joined the UCSF Cardiac Stem Cell Translational Development Program (California, USA) as a post-doctoral researcher and later as a research specialist. He also teaches at the University of Helsinki.
Samuel is the Head of Operations at Blueprint Genetics as well as a co-founder of the company. He is an expert in genome analysis technologies and has extensive experience in bioinformatics and cancer genomics research. Samuel received his PhD from the University of Helsinki and completed his post-doctoral research at Stanford University. At Stanford, he developed high-throughput sequencing technologies such as the Oligonucleotide-Selective Sequencing (OS-Seq™). He is an adjunct professor in genetics at the University of Helsinki, an author of several high-impact publications, and an inventor in patents of DNA sequencing methods.
Tero-Pekka is the Chief Medical Officer, President, and a co-founder of Blueprint Genetics. He is based in San Francisco and in charge of North American operations. He designs diagnostic panels and mutation databases and works with clinical evaluation of genetic data. Tero-Pekka has a MD-PhD degree and is specialized in pediatrics and pediatric cardiology. He has a PhD in molecular and cellular biology as well. In 2007, he continued his research at Stanford University, School of Medicine. During this three year postdoctoral training, he focused on the molecular genetic mechanisms of cardiovascular diseases. He continued his cardiovascular research at the University of Helsinki as a principal investigator and the head of an academic research group.
News
A Finnish study finds evidence indicating the JPH2 gene to be causative in hypertrophic cardiomyopathy
Published on September 21, 2018
This study1 provides the first substantial evidence of the JPH2 gene associating with monogenic familial hypertrophic cardiomyopathy (HCM). The study ‘Heterozygous Junctophilin-2 (JPH2) p.(Thr161Lys) is a monogenic cause for HCM with heart failure’ was published recently in PLOS ONE. Hypertrophic cardiomyopathy is considered the most common form of inherited cardiomyopathies,…
Read moreSee all news
Events
Paediatrician days 2018
Lastenlääkäripäivät 2018
–
Ajurinkatu 16, Kuopio, Finland
Annual Pediatric Association organises an educational days for paediatrician and those who has specialised on the paediatric diseases. The educational paediatric days will be held in Kuopio from 7th to 8th November. We will be attending this event and welcome you to visit us at our booth to discuss the…
Read moreSee all events